Eli Lilly and Company said that the U.S. Food and Drug Administration (FDA) granted a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen®, which can administer a complete month of therapy in one device. Lilly is giving people more options with the Zepbound KwikPen. This helps make sure that patients and healthcare providers may choose the solution that works best for their requirements, preferences, and situations. Patients who have a valid prescription and choose to pay for their medications themselves through LillyDirect® can get all doses of Zepbound in a KwikPen or single-dose vial. The 2.5 mg dose starts at $299 per month.
“Zepbound is the #1 prescribed injectable obesity management medication, helping adults achieve meaningful and clinically proven weight loss, on average, up to 50 pounds, as seen in SURMOUNT-5,” stated Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. “As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines.”
In 2025, more than 1 million people got Lilly therapies through LillyDirect, which offers self-pay prices that are 50% or more lower than the list price of alternative incretin (GLP-1) drugs for obesity. In 2025, one out of every three new patients who started taking a branded weight management drug was given Zepbound self-pay vials. This shows that there is a lot of demand for this new access model and that Lilly is dedicated to helping people with obesity.
“After trying so many times to lose weight over the years, I’m grateful I talked to my doctor about Zepbound,” stated Jacob M., Zepbound patient and LillyDirect customer. “Along with diet and exercise, Zepbound has helped me make real, lasting progress. And LillyDirect made getting the medicine simple, from filling my prescription to home delivery. I feel supported at every step of my weight loss journey.”
The great efficacy profile of Zepbound is shown by the considerable demand for it. In the SURMOUNT-1 experiment, adults who took Zepbound 15 mg lost on average of 20.9% of their body weight over 72 weeks, whereas those that took a placebo lost only 3.1%. In the open-label SURMOUNT-5 research, persons who used Zepbound lost an average of 50 pounds (20.2% of their body weight), while people who took injectable Wegovy lost an average of 33 pounds (13.7% of their body weight).
Zepbound is a prescription injectable drug that may help adults who are overweight or obese who have health concerns related to their weight lose weight and keep it off. Adults with moderate to severe obstructive sleep apnoea (OSA) and obesity may also find that Zepbound helps them improve their OSA. Zepbound has tirzepatide in it; thus, you shouldn’t use it with other products that include tirzepatide in them or any GLP-1 receptor agonist drugs. We do not know whether Zepbound is safe and effective for children.
You can get Zepbound in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg. The 2.5 mg dose is the first one, not the one that is approved for long-term use. For weight loss and long-term maintenance, the recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected under the skin once a week. For OSA, the suggested maintenance doses are 10 mg or 15 mg.
Results differ from person to person. Zepbound is not intended for weight loss for cosmetic reasons. Zepbound may make tumors grow in the thyroid, which can lead to thyroid cancer. If you notice any of the following signs, you should see a doctor: a lump or swelling in the neck, hoarseness, problems swallowing, or shortness of breath. Tell your doctor if you develop any of these symptoms. If you or anybody in your family has ever had medullary thyroid carcinoma (MTC), you should not use Zepbound. If you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), you should not use Zepbound. Don’t use Zepbound if you’ve had a bad allergic reaction to tirzepatide or any of its ingredients.
Disclaimer:
The information contained in this article is for educational and informational purposes only and is not intended as a health advice. We would ask you to consult a qualified professional or medical expert to gain additional knowledge before you choose to consume any product or perform any exercise.
